Anergix LLC is an early phase biotechnology company developing a combined cell/gene therapy treatment for multiple sclerosis, a disease that affects roughly 400,000 Americans and 2.5 million people worldwide. Our therapeutic strategy is to present immune regulatory cells with low doses of the myelin peptide antigen thereby inducing immune tolerance to the suspected myelin antigens thought to cause the autoimmune response. To deliver these myelin peptides, Anergix sequesters proprietary peptide-secreting cells in a small device implanted under the skin. Thus continuous, low dose therapeutic levels of the peptide are generated on a systemic basis – with excellent results in mouse models of the disease. This approach has additional therapeutic applications to other autoimmune diseases.

For more information contact: Katherine Louie, Ph.D. (CTO) or David Graham (General Manager)
anergix4ms.com